Although management's concerns imply the potential for near-term headwinds, longer-term tailwinds remain that support further equity upside
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The company developed Micro-Invasive Glaucoma Surgery (MIGS) to serve as an alternative to the glaucoma treatment and management paradigm. MIGS procedures involve the insertion of a micro-scale device or drug delivery system from within the eye's anterior chamber through a small corneal incision. The company's MIGS devices are designed to reduce intraocular pressure by restoring the natural outflow pathways for aqueous humor. The company's products include iStent trabecular micro-bypass stent, and iStent Inject trabecular micro-bypass stent.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.